, , ,

<<


 >>  ()
Pages:     | 1 |   ...   | 11 | 12 || 14 |

2- - -2010 13-15 2010, , ...

-- [ 13 ] --

In the past several years our understanding of genetic background of common immune related diseases increased dramatically. Genome wide association studies (GWAS) have recently become available and lead to discovery of dozens of associated loci in complex diseases such as type 1 diabetes, celiac disease, Crohns disease, systemic lupus erythematosus, rheumatoid arthritis and others. Many of these loci are shared between two, three or more diseases. The new associated variants still can explain only 20-50% of genetic susceptibility to these diseases. The remaining heritability might be explained by yet undiscovered rare variants, copy-number polymorphisms, or other variants, which can not be detected by GWAS-methods.

It is remarkable, that most autoimmune loci (in fact, all except the HLA), have a minor effect on the disease susceptibility. The odds ratio (OR) for most loci is in the range of 1.2-1.3 or even lower. Many associated polymorphisms are not the functional variants, but proxies of the real mutations. With these limitations, is it possible to use our current genetic knowledge in clinical practice, for prediction of genetic risk of autoimmunity? In this presentation I will discuss the perspectives and problems of genetic risk tests in autoimmune and inflammatory diseases, will give an example of using the genetic risk information in PreventCD program, and will discuss the ethical issues of genetic tests in complex diseases.

ZHIGACHEVA I.V., EVSEENKO L.S., MOKHOVA E.N.

Russian Academy of Sciences, N. M. Emanuel Institute of Biochemical Physics, Moscow, Russia POTASSIUM FENOZAN AND POSSIBLE MECHANISMS OF ITS ACTION ON THE FUNCTIONAL STATUS OF MITOCHONDRIA IIN LOW AND ULTRA-LOW DOSES In all cells and all their frequent formation of reactive oxygen species (ROS). In a normal steady-state level of ROS in organs and tissues is very low (around 10-10 - 10-11 M) due to the prevalence of these powerful enzymatic and non-enzymatic regulatory systems of accumulation and elimination of ROS. Value pro-oxidants and antioxidants determines, develops, and whether progress oxidative stress and as a result of free radical pathology. Pathological consequences arise when excessive accumulation of ROS and activation of lipid peroxidation (LPO).

Generated in mitochondria reactive oxygen species (ROS) can damage not only the mitochondrial biomolecules, such as mitochondrial DNA, but and various intracellular structures. So, creation and research of new antioxidants are related to basic medical problems.

The problem of selecting the most effective concentrations of drugs, in particular antioxidants are especially important in view of the fact that many biologically active substances (BAS) have a dose-dependent in the manifestation of its activity (Burlakova EB et al, 2003). The aim of our work was to study the effect of various antioxidant potassium fenozan concentrations on lipid peroxidation in the membranes of mitochondria. Oxidative stress causes long-term storage "aging" of mitochondria (4 mg protein) in 0.5 ml incubation medium (70 mM KCl, 1 KH2PO4, pH 7,4). "Aging" activated LPO. Introduction drug 10-8- 10-16 M and 10-18-10-22M in the incubation medium reduced the intensity of mitochondrial lipid peroxidation to control values.

We proposed that fenozan produced its protective effect via different mechanisms within various concentration intervals To elucidation this question the number of fenozan molecules in the sample, and relation between this value and the numbers of mitochondria in each sample were calculated. It is known that 1 M of any substance contains 6.02x1023 molecules in 1 liter. At 10- M fenozan concentration, the well contains 3x1012 fenozan molecule. Calculation (according to K. Schwerzmann et al., 1986) shows that the 0.5 ml well contains about 3x1010 mitochondria, as the well contains about 4 mg mitochondrial protein. Consequently, in the well the relation between number of fenozan molecules and number of mitochondria is about 100 (3x1012 / 3x =100). One can assume that this concentration of the drug is embedded in the membrane and interacts with the lipid hydroperoxides.At 10-11 M fenozan concentration, the sample contains 3x109 fenozan molecule, and thus, the above calculated ration decreases to 0,1 fenozan molecule per one mitochondria. Probably, at such low concentration potassium fenozan fenozan form associates with water molecules and interacts with receptors on the surface of mitochondria (Ryzhkina IS et al, 2009). And, finally, at a concentration pereprata 10-22M, in the sample are almost no molecules potassium fenozan. In this case, the biological effect of the drug, apparently related to changes in the structure of water (M. Chaplin, 2000). These data suggest that the most effective use of the drug for medical purposes may be in the concentration range 10-9-10-14M, when the drug interacts with receptors of biological membranes. Future research should elucidate the mechanism of fenazin and similar biological active substances functioning at such extremely low concentration.

ZHIGACHEVA I.V., EVSEENKO L.S., BURLAKOVA E.B.

Russian Academy of Sciences, N. M. Emanuel Institute of Biochemical Physics, Moscow, Russia POTASSIUM FENOZAN - PREPARATION FOR THE PROTECTION OF TISSUES IN HYPOXIA Mitochondria being the energy exchange regulating site play an important role in the organism response to stress conditions. In normal (aerobic conditions), mitochondrial respiratory chain generates a fraction of O2- and H2O2, performing the role of signaling molecules necessary for life of the organism (V.P. Skulachev, 2001). However, in conditions of hypoxia and ischemia, production of reactive oxygen species (ROS) by mitochondria increases sharply (T.

Kristian, 2000). This decreases the activity of antioxidant enzymes (SOD, catalase, MPO) (A.X.

Kogan et al, 1992). That limits the ability of cells to inactivate ROS. One can assume that the basic properties of drugs that lead to resistance of cells and the whole organism to hypoxia and ischemia, a reduction of excessive ROS production, leading to activation of lipid peroxidation (LPO) in biological membranes. To investigate the presence of drugs in such properties has developed a model of "aging" (long-term storage) of the mitochondria at room temperature.

Since it is known that sterically hindered phenols, in most cases, have antioxidant properties, as the object of study was selected product fenozan potassium (potassium salt of 2,6-di-tert-butyl-4 hydroxyphenyl-propionic acid), which added to the incubation medium mitochondria.

Aging resulted in enhancing the fluorescence intensity of LPO products by a factor of to 4. The addition of the preparation resulted in decreasing the LPO products fluorescence: the preparation concentration 10-5, 10-6, and 10-7 M produced an insignificant effect on the intensity of LPO processes. The potassium phenozan concentrations 10-8- 10-16 and 10-18 - 10-22 M resulted in decreasing the fluorescence intensity of LPO products to a control level.

For further research, we have chosen the concentration of 10-14 M, decreasing the production of ROS to the control values.

Rats the drug at this dose is 1 hour after injection resulted in higher content of unsaturated and lower content of saturated fatty acids in the membranes of liver mitochondria.

The content of stearic acid decreased in 1,3 times, palmitic - in 1,5 times. At the same time, the content palmitooleic, linoleic and linolenic acids increased at 1,3, 1,2, 3,5 times, respectively. As a result, the ratio of unsaturated to saturated fatty acids increased from 1,27 0,10 to 2,04 0,06. It should be emphasized that 1 hour after injection in the content of the total amount of oleic, linoleic and linolievoy acids in the membranes of mitochondria has been an increase from 30 to 42-45%. The contribution linoleic acid in the total amount of unsaturated fatty acids with 18 carbon atoms increased from 3% in control to 33% in the experiment. Similar changes in fatty acid composition of membranes were observed during the adaptation of animals to cold (Spiridonova V.A., 1982). After 3 hours in total lipid fraction of membranes of mitochondria the percentage of saturated fatty acids is reduced, and even some unsaturated growing. The content of arachidonic acid in the membranes of mitochondria one hour after injection was reduced by 20%, and 3 hours later - at 40%, which in turn helped reduce the intensity of lipid peroxidation in the cells.

These changes are reflected and physiological indices. The introduction of the drug to animals in this dose by 20-30% increased survival of animals under conditions of hypoxia and low temperature stress. These results indicate the possibility of using potassium fenozan for protecting tissues from free radical attack in conditions of ischemia and hypoxia.

YU.N. ZHUKOVA, M.G.ALEKSEEVA, O.B.BEKKER, V.N.DANILENKO Vavilov Institute for General Genetics, RAS, Moscow, Russia, e-mail: valird@rutenia.ru CONSTRUCTION OF BACTERIAL TEST-SYSTEM CONTAINING APHVIII/PKNB IN ESCHERICHIA COLI FOR MYCOBACTERIUM TUBERCULOSIS PROTEIN KINASE PKNB SCREENING One of the main current pharmaceutic goals is specific targets of many wide spreaded diseases. Mycobacterium tuberculosis infects nearly one-third of the words population and cause more than two million deaths per year.

Kinases are ubiquitous regulatory enzymes, which can be used as pharmaceutical targets.

Based upon published data, serine-threonine protein kinases (STPKs) pKnB and pKnG play an important role in Mycobacterium tuberculosis strain virulence and pathogenecity. Detailed analysis of STPKs structures and its regulation mechanism and its putative substrates could be useful for create therapeutic application as possible targets SRPKs for design a new antimicrobial drugs.

We have designed AphVIII/PknB test-system in E.coli containing aminoglycosyde phosphotransferase type VIII (AphVIII) which provide antibiotic resistance for bacterial culture.

In order to increase AphVIII and PknB substrates phosphorylation sites two modifications near the AphVIII Ser-146 in activation loop have been carried out. Three amino acids in each mutant was substituted to the specific amino acids which takes place in M.tuberculosis PknB activation loop site and PknB substrate phosphorylation site. Mutagenesis was carried out by point mutation technique. As a result we have obtained two mutants Ser 146 AphVIII proteins:

AVAEGS146VDLEDAVAEGT146QDLFD and AVAEGS146VDLEDAVAEGT146QTLED.

Obtained mutant fragments was sequenced to confirm corresponding nucleotides and after that constructions was cloned in pET32a expression vector, which contained PknB catalytic domain sequence. AphVIII and PknB genes expression was inspected after induction by SDS-PAGE technique. Kanamycin resistance was inspected for the E.coli strains, which contain all of the obtained constructions. Vectors containing both AphVIII and PknB find rather kanamycin resistance than versions containing AphVIII only. This fact could be explained by phosphorylation AphVIII with protein kinase PknB. Optimal construction for test-system was choosed on the assumption of the kanamycin resistance alteration range for E.coli with variations AphVIII/PknB combinations. We used standard STPKs inhibitors, particularly indolylmaleimides, for validation of the test-system. Addition of inhibitors interfere with phosphorylation and forces E.coli cells to be sensitive to antibiotic kanamycin.

This study was supported by Russian Foundation for Basic Research grant 09-04- Biotarget pointed screening of new generation drugs on basic of M.tuberculosis protein kinase inhibitors.

ZLOBIN A.E.

Mathematician (Lomonosov Moscow State University, Faculty of Computational Mathematics and Cybernetics) Ph.D. (Bauman Moscow State Technical University) 107258, Moscow, Russian Federation, aezlobin@yandex.ru ATOM OF HYDROGEN AS A METRIC BASE IN ORGANIC WORLD For the first time main results of this study were reported by the author during the conference "A body of a man as socio-cultural phenomenon: experience of interdisciplinary analysis" which was held in Russian University of Physical Education, Sport and Tourism" (RGUFKSIT-GTSOLIFK) in april 28-29, 2009.

In 90th years the author has already made publications concerning some results of this study too. All these publications stated mathematical formula which links between themselves four constants: length of a circle over its diameter (P=3,1415), base of natural logarithms (e=2,7182), golden proportion (F=1,6180) and so-called irrational one number (j=1,0079). Accurate view of this formula is: (PxF)/(exp(F))=j. The author noted that metric properties of this formula reflect not only geometry of a body of a man, but also geometry of animate nature in general. In addition the author stated that the formula sets very convenient system of measurements, because j=1,0079 is the relative mass of atom of hydrogen (H) simultaneously. For example: when using this relative system of measurements, diameter of atom of hydrogen (H) approximately equal 1/P, diameter of atom of gold (Au) approximately equal 1, and diameter of atom of potassium (K) approximately equal golden proportion. This wonderful fact really confirms correctness of the term "gold proportion" as a historical tradition. Some interesting conclusions may be stated for other chemical elements too.

Thus, the formula sets quite accurate correspondence between well-known mathematical constants and well-known physical and chemical relative parameter. Such properties of the formula allow to describe atoms and molecules by strict methods of mathematics and to explain presence of strictly determined geometrical proportions in organic world (for example - presence of gold proportion in objects of animate nature). It is well-known that presence of potassium (K) very important for growth of vegetation. There is quite well explanation why gold proportion can be discovered in different samples of vegetation. By another words, presence of concrete proportions on micro level explain presence the same proportions on macro level. It is useful to apply this logic for explanation of principles of working of brain too. In this case, the working of brain is possible to describe as working of special organic computer, based on usage of mentioned numerical properties of atoms. It is not excluded that so-called chemical brain elements (for example - gold) are necessary for effective number generation during computational process. Such method of computations seems to be possible on the base of neuron net and able to explain cognitive properties of brain. Results of this study may apply in different branches of biology, physics, chemistry, mathematics, cybernetics, computer science, artificial intelligence, cognitive science, nanotechnology etc.

.., ............................................................................................... ............................ ..1, ..1, ..1, ..1, ..1, ..1, ..1, ..1, ..1, ..2................ IN VITRO............................................................................................................................ .., .., .., ........................................................ IN VITRO............................................................................................... .. 1, ..2, .. 1...................................................................... -3- APHVIII - : - ............................. .., .., .., .., .., .., ..1, .., .., ..2.......................................... ..................... ........................................................................................................................................... - ..................................................................................................................................................... ..2, . .1,2................................................................................................ ................................ . ., .., . ., . ................................ .................................................................................................. ........................................................................................................................................... .................................................................................................................................................................. ..1, ..2, ..1...................................................................... GYRODACTYLUS SALARIS: , .................................................................................... ............................................................................................................................................ -....................... ........................................................................................................................................... ............................................................................................................................ ........................................................................................................................................... ............................................................................................................................ ..*, ..*, ..*, .

.*, ..*, ..*, ..**, ..**, ..**.............................................. ................... - - : ESCHERICHIA COLI APHVIII/PK25........................................................................................................................................... .., .., .., .., .., ................. ........................................................................................ ................................................................................................................................................. ........................................................................................... .., .., ........................................................................ ............................................... .............................................................................................................................................. - - .., .., .., ............................................. ......... .., .., .., ............................................. ....................................................................................................... .., 1 2, *, .. 1, .. 1, .. 2, .. 3, .. 1, .. 2, .. 1............................................................... LACTOBACILLUS : C ................................................................... . ., . .................................................................................................................... ........................................................................ .., .., .., .., .................................. ..................................................................................................... ..2, ..2, ..2, ..1,2.......................................... PENICILLIUM SP............................................................................... .., ......................................................................................................... .................................................................. ....................................................................................................................................... ........................................................................................................................ .. ..-...................................................................................................................... ......................................................................................................................... .., .., ................................................................................. SPIRULINA NOSTOC ............................................................................... .., .., .., .., ................................ - ............................................................. .............................................................................................................................................. ................................................................................. .., .., ..................................................................................... ............................................................................................................................ ...1, ..1, ..1,2, ̨ ..1, ..1,2.............. PENICILLIUM CANESCENS...................................................................................................................... .., .., ....................................................................................... ........ ........................................................................................................................................... - .................................................. .., .., ....................................................................... ............................................................................ . ., . ., . ., . ..................................................... -, - ........................................ .., .., .., ..2, .., - ..3......................................................................................................................................................... , .................................................................................................................................................. ..1, ..1, ..1, ..2................................................ ........................................................ .., .., ............................................................................................ BLSI- GLAI- .......................................................................................................................................................... .., ........................................................................................................................ ........................................................................................... ............................................................................................................................................ ..................................................................................................................... ....................................................................................................................................... () : , , ................................................................................................................................................. .., .., .................................................................................. .............................................................. ..............................................................................

................................................................. : ........................................................................... .., ................................................................................................................ ............................................................................ .., ................................................................................................................ - ........ .. .................................................................................................................................... - .................... .., .., ................................................................................ ....................... .., .., .................................................................................... ............................................... .., .., .., ........................................................... - E.COLI APHVIII/PKNB PKNB MYCOBACTERIUM TUBERCULOSIS.................................. .., .............................................................................................................................. : ............. ..1, ..2, ..1, ..2, ..1.......................................................................................................................................................... - ............................................. .., .., .., ............................................................. .............. .., .., .., .., .., ............................................................................................................................................................. - III - .................................................................................................................................................... .., .................................................................................................................. : , , ....................................................... ............................................................................................................................................... .............................. .............................................................................................................................................. ........................................................................................................................................... ..1, ..2.............................................................................................................. »:

............................................................................................................................. ..................................................................................................................................... .................. .., .., ..................................................................... - (H1N1).................................................................................................................... .., .................................................................................................. IN VITRO BRASSICA NAPUS................... .., .., .., .., ..................................... () .............................................................................................................................................. .. 1, .. 1, .. 1, .. 1, .. 1,3,4, . 2, . 2.................................................................................................................. ZILEUTON.................................................................................................................................................. .., .., ................................................................................ .................................................................................................... ..1, ..2, ..1, ..1, ..1, ..3, ..4, 5, ..1, ..1................ : .................................................................................................... .., .., ............................................................................ () GLUCONOBACTER OXYDANS....................................................... ............................................................................................................................................ .................................................................. .., ........................................................................................................ .. .., ........................................................................................................ .. .*, .. **, .. **.......................................................................... , ........................................................................... . ., . ., . ., . ., . ., . ., . ............................................................................................................ .......................................................... .., .., ....................................................................... HDAC- : .................................................................................................................................................. .., .., .............................................................................................. RHODOCOCCUS ERYTHROPOLIS -858 ......................................................................................................................................... .., .., .............................................................................. Ю - ................................................................................................................................ M.MA., .A., .A., .B., .B., .B................................................................................

.............................................. 3 .................................................................................................... ..1, ..2, ..3, ..3, ..3, ..4....................................................................................................................................................... . ....................................................................................................................... ..1, .. 2, .. 2, .. 2, .. 2, .. 3.................................................................................................................................... ............... .1., ..2, ..2............................................................ ܻ: ........................ ........................................................................................................................................ (, , )................................................................................. ..1), ..1), ..1), ..1), .. 1), ..1), ..1), ..1), ..2), ..2) ......................................................................................................... ............................................................................................................................................... .................................................................................................................................. .., . ., .., .., ............................... ............... ......................................................................................................................................... : , , ........................................................................................................................................... .., .., ......................................................................... ......................................................................................................... .., .., .., .................................................. , ............................................................................................................................................ .., .., .., _..................................................... - E.COLI APHVIII/LPK17 AFSK ................... ..1, ..2, ..2, ..1, ................................................................................................................................................................... .............................................................. Ҩ ......................................................................................................................................... , S.................................................................................................... .., .., .., .., ........... ()()() - ..................................................................................................... .., ................................................................................................................ HALOCYNTHIA AURANTIUM. ........................ .., .., .., .., ...................... LENTINUS TIGRINUS............................................................................................................................... .............................................................................................................................. .......................................... .., .., .., ................................. - - BIFIDOBACTERIUM LONGUM B379M.................................................................................................................. ..1, ..1, ..1, . 1., . 1., ..2, .. 2, ..1, .. 2,3..................................... - - ............................................................................................ .., - .., .., ..................... , ........... ..1, ..1, ..2, ..1, ..1, ..3, ..3, ..2........................................................................... . .., .., .., .......................................... .......................................................................... .., ........................................................................................... BIO HAYAT........................................................................................... ..2, ..2, ..2, ..1,2, . .1,2.. PENICILLIUM SP.

........................................................................................... . ., . ., . ....................................................................... 3: , ............................................................................................................................................... .., .., .., .., .................. .................................................................................................................... .., .., .., .., ................... ................... ..1,2.................................................................................................................................. ...................................................................................................................................... ............................................................................................................................................. ..................................................... .., ...................................................


............................................... , F1F0-, .......... .., .., ................................................................... , ............................................................ ..1, ..2, . .1,2.................................................... , PENICILLIUM VERRUCULOSUM, XYL A FPLC ........................ ........................................................................................................................................... ............................................................................................. ................................................................................................................................. - / .. .., .., .., ........................................................ ........................ .., .., ........................................................................................... .................................................................................................................... . ., . ., . ., . ., . ., .

.............................................................................................................................................................. DROSOPHILA MELANOGASTER ..................................................................................................... ............................................................................................................................................. 16- .................................................................... .., ............................................................................................................. .......................................................................................................................... ., ............................................................................................... ...................................................................................... .., .., .................................................................................... ................................................................................................................................. .., .................................................................................................. -: .................................... . .1,2, ..1, ..2, ..1,2, .. ..2, ..2, ..2, ..2, ..2, ..2, ..2, ..2, ..2, . .1, ..3, ..3, ..3, . .3, . .3, . .3....................................................................................................................................... ....................................................................................................................................... .., .., .., .................................................... ................. ., ., Ĩ ................................................................................................ ........................................................ .. , .. , .. , .. .................................................. 3D ........................................................................................... .., .., ............................................................................. ............................................ .., .., ...................................................................... :

, ............................................................................................. .., .., ...................................................................................... ................................................................. ..1, ..1, ..1, ..1, , .2, ..2............................................................................................................................ N- ..... ..1,2, ..2, ..1, ..1, ..2, .. 2, .. 1, .2.............................................................................. ......................................................................................................................................... .., .., .., .., .., ......................................................................................................................................... - [1,2-A]-.................. .., .., .., .., .., .., .., .., .., ................................. IN SILICO ....................................................................................... .., .., .., .., .., .., ............................................................................................................................. .................................................................................................................... . ....................................................................................................................................... : , , ..................... 1 .., 2 .., 1 .., 1 .................................. ...... .., .., .., .., .., .., ......................................................................................................................................... IN VITRO................................................................................... .......................................................................................................................................... - ..................................... ., . . ................................................................................................................ .................................................................................................................. .1., .. 1, 2, .. 1,2, ..2, ..1,3, ..1,2, ..2.................................................................................................................... ...


......................................................................................................................................... .., .., .., .., .., .., ..................................................................................... - G " 3253".................................................................................................................................... .., ................................................................................................................. , .................................................................. ............................................................................................................................................. - ......................................................................................... .., .., .., ..................................................... ................................................................................................. .., .., ................................................................................. ........................ . ., . ........................................................................................................... ..................................................................................... .., .., .., ......................................... PASS....................................................................................................................................................... ..1, ..2..................................................................................................... ................................................................................................................................ ......................................................................................................................................... SACCHAROMYCES CEREVISIAE CANDIDA ALBICANS.............................. ..1, ..2, .. 1, ..2........................................... ............................................................. ........................................................................................................................................... : ........................................................................................................................................ .., .., .., .............................................. - . .................................. . ., .., .., ....................................................................... LEUCONOSTOC MESENTEROIDES................................................. . ., .., .......................................................................................... .......................................................................................................................... . 1, 2, 3, 4............................................................................................................................... : - ..................................................................................................... .., .., .., ..................................... : , , ....................................................................................................... .. *, .. ***, .. **, - .. ***, ..***................................................................................................................................................................. ................................................................................................................................................................ ABDULRAGIMBEKOV Y.M., OMAROV F.S............................................................................................. INDUSTRIAL AQUACULTURE OF ALGAE IN AZERBAIJAN.................................................................. ABRAMOVA E.G.1, SHARAPOVA N.A.1, NIKIFOROV A. K.1, KIREEV M.N.1, SAVITSKAYA L.V.1, GENERALOV S.V.1, MIKHEEVA T.A.1, MINAEVA L.N.1, GALKINA M.V.1, BUTYRSKIY A.YU.2............. ASSESSMENT OF ACTIVITY OF ANTI-RABIES SERA AND IMMUNOGLOBULIN IN VITRO.......................................................... M. G. ALEKSEEVA 1, S. M. ELIZAROV 2, V. N. DANILENKO 1............................................................... DEPENDENCE OF AMINOGLYCOSIDE 3-PHOSPHOTRANSFERASE APHVIII ACTIVITY ON THE PHOSPHORYLATION WITH SERINE/THREONINE PROTEIN KINASES: THE BASIS OF DESIGN OF TEST SYSTEMS FOR THE SCREENING OF PROTEIN KINASE INHIBITORS....................................................... ALEKSEEVA O.M., MILL E.M., ALBANTOVA A.A., BINYUKOV V. I., EROKHIN V.N., KIM YU.A.1, KREMENTSOVA A.V., GOLOSHCHAPOV A. N., BURLAKOVA E.B., FATTACHOV S.G.2...................... ANTITUMOR EFFECT OF PLANT GROWTH REGULATOR - MELAFEN.................................................. ALMS KARL........................................................................................................................................... DEVELOPMENT OF NEW TECHNOLOGIES FOR THE GLOBAL AQUACULTURE INDUSTRY......................................................... ALTAIULY S.............................................................................................................................................. INTENSIFYING THE DRYING PROCESS OF PHOSPHATIDIC EMULSION OF SUNFLOWER OILS IN THE ROTATION-FILM APPARATUS................ ANDRIANOV R.M.2, SINITSYN A.P.1,2................................................................................................... ADSORPTION BEHAVIOR OF CELLULOLITIC PREPARATIONS ON LIGNOCELLULOSIC SUBSTRATES.................................................. ANOKHINA V.S., OVCHINNIKOVA S.I., VASCTHENKO P.S., POCHOLCHENKO L.A............................ STUDYING OF INFLUENCE OF COMPONENTAL STRUCTURE OF FISH FORAGES ON PARAMETERS OF THEIR QUALITY DURING STORAGE..................................................................................................... APRYSHKO G.N...................................................................................................................................... INFORMATION TECHNOLOGIES IN THE SYSTEM OF SEARCHING ANTITUMOR SUBSTANCES........ ARTAMONOVA V.S.1, KHAIMINA O.V.2, MAKHROV A.A.1................................................................. GYRODACTYLUS SALARIS RESISTANCE IN ATLANTIC SALMON: PERSPECTIVES FROM MITOCHONDRIAL DNA........................................................................................................................ AVERINA O.V., DALELOVA D.K.............................................................................................................. ANTIMICROBIAL SUSCEPTIBILITY OF BIFIDOBACTERIA....................................................................... AVERINA O.V., ZAKHAREVICH N.V., DANILENKO V.N......................................................................... WHIB-LIKE PROTEINS OF BIFIDOBACTERIA.......................................................................................... AVKSENTYEVA O. A., ZHMURKO V.V., PETRENKO V. A., ZHORNYAK YU.V......................................... GENES CONTROLLING PLANT DEVELOPMENT RATE AS A MODEL TO STUDY MORPHOGENESIS PROCESSES IN VITRO............................................................................................................................ BALAKIN K.V.................................... ....................................................................................................... NATIONAL BIOSCREENING NETWORK AS INFRASTRUCTURE FOR SYSTEMATIC DEVELOPMENT OF PHARMACEUTICAL COMPOUND-LEADERS BARSUKOV A.K.*, KUZNETSOV A.I.*, NESTEROVA O.YU.*, KOZHEVNIKOVA O.V.*, ZHELTYSHEV E.N.*, KHRAMOV V.A.*, PANIN A.N.**, SMOLENSKY V.I.**, ULASOV V.I.**................................................... IMMUNOGLOBULIN AND ALBUMIN BIOPHARMACEUTICALS PRODUCTION FROM OFF-GRADE CRUDE MATERIALS.............................. O.B.BEKKER, M. G. ALEKSEEVA, S. M. ELIZAROV, V.N.DANILENKO.................................................... NEW TEST SYSTEM FOR SCREENING INGIBITORS OF SERIN-TREONIN PROTEIN KINASES: E. COLI APHVIII/PK25......................................................................................................................................... BELKIN V.G., KALENIK T.K., GRISHIN A.S., DOLGOVA T.G., FISCHENKO E.S., MOTKINA E.V.............. FOOD BIOTECHNOLOGIES OF PRODUCTS OF LONG STORAGE OF A SPECIAL PURPOSE............ JAN BERGLOF......................................................................................................................................... TRENDS IN IMAC TAG CAPTURE: FROM PROTEOMICS INTO BIO-PROCESS APPLICATIONS.......... ALEX BERLIN, PH.D. VICE PRESIDENT OF R&D........................................................................................ ROBUST ENZYMES FOR COMMERICALLY VIABLE BIOCHEMICAL BIOREFINERIES............................ BOGDANOVA J.A., SEDYAKINA N.E., AVRAMENKO G.V.................................................................... EFFECT OF DICARBOXYLIC ACIDS AS CROSS-LINKING AGENTS ON CHARACTERISTICS OF INSULIN LOADED CHITOSAN MICROCAPSULES.............................................................................. BORISENKO E.G., GORYN K.V., KANOCHKINA M.S., NGUEN CHYONG ZANG................................. THE YEAST-BACTERIAL EDIBLE PRODUCTS BASED ON THE PRIMARY AND SECONDARY AGROINDUSTRIAL RAW MATERIALS................... CLEMENS G. BORKENSTEIN1, JOSEF KNOBLECHNER1, HEIKE FRHWIRTH1, MICHAEL SCHAGERL2.. MASS CULTIVATION OF CHLORELLA EMERSONII WITH FLUE GAS FROM THE COMBUSTION OF FOSSIL AND SURROGATE FUELS........................................................................................................... BOTINA S.G. 1, 2,*, GLAZOVA A.A.1, KOROBAN N.V.2, ZHILENKOVA .G.3, POLUEKTOVA E.U.1, ZINCHENKO V.V.2, DANILENKO V.N.1.................................................................................................. NTIBACTERIAL DRUG RESISTANCE OF POTENTIALLY PROBIOTIC LACTOBACILLI FROM HUMAN GASTROINTESNINAL ICROBIOME: DETERMINATION FND TRANSFERABILITY OF THE RESISTENCE GENES................................................................................................................................................... N.V. BOVIN............................................................................................................................................. SUPRAMOLECULAR CHEMISTRY AGAINST INFLUENZA VIRUS........................................................................................... BRAGIN V. A., REVINA E. S..................................................................................................................... CHANGES IN FATTI ACID COMPOSITION OF HUMAN PERIPHERAL BLOOD ERYTHROCYTES INDUCID NITRIC OXIDE......................................................................................................................... BUROVA Y.A., LUKATKIN A.A., IBRAGIMOVA S.A., REVIN V.V., GROSHEV V.M................................. EFFECT OF CHITIN ON BIOPREPARATION PROPERTIES...................................................................... BUSHINA E.V.2, ROZHKOVA A.M.2, SEMENOVA M.V.2, SINITSYN A.P.1,2.......................................... DEVELOPMENT OF HETEROLOGOUS PECTINLYASE STRAIN-PRODUCER ON THE BASIS OF RECOMBINANT STRAIN PENICILLIUM SP............................................................................................. SHANG-YUAN CHEN 1*, CHEN-YEON CHU2, MING-JEN CHENG 3 AND CHIU-YUE LIN 4........................................................................................... A BIO-HYDROGEN BASED ENERGY SELF-SUFFICIENT APPROACH FOR THE AUTONOMOUS HOUSE........................................ CHERNYSH S.I......................................................................................................................................... INSECT IMMUNE SYSTEM AS A LIVING PHARMACOPEIA: FROM LABORATORY RESEARCH TO CLINICAL USE.................................... DANILENKO V.N..................................................................................................................................... NATIONAL NETWORK OF BIOLOGICAL SCREENNG (NNBC) IN RUSSIA: THE CONCEPT, NOVEL PARADIGMS AND BIOLOGICAL ASPECTS.......................................................................................... DEMIN O.V.............................................................................................................................................. MODELING IN SYSTEMS BIOLOGY: APPLICATIONS TO THE PROBLEMS ARISING IN BIOTECH AND PHARMA INDUSTRY............................................................................................................................... DENISOV E.T., DENISOVA T.G................................................................................................................ FREE RADICAL GENERATION AND ANTIMALARIAL ACIVITY OF TRICYCLIC ANALOGS OF ARTEMISININ.......................................................................................................................................... DENISOVA T.G., DENISOV E.T................................................................................................................ DISSOCIATION ENERGIES OF BONDS AND ANTIOXIDANT ACTIVITY OF NATURAL PHENOLS................................................................................................................................................................ DEVJATKIN A.A., REVIN V.V., RAZUMOVSKAYA O.V........................................................................... INFLUENCES ON MECHANISMS OF CELLULAR DESTRUCTION OF NATURAL ANTIOXIDANTS......................................................... EDVARDSEN TORGEIR............................................................................................................................ INTRODUCTION TO AQUACULTURE FOR FOOD, MEDICINE, FUELS AND CHEMICALS.......................................................... SEAN EKINS 1, 2, 3, 4.............................................................................................................................. OPPORTUNITIES FOR COMPUTATIONAL DRUG DISCOVERY AND SCREENING: IMPROVING HIT QUALITY AND FACILITATING COLLABORATIONS......................................................................................................................................... ANDRE FAAIJ.......................................................................................................................................... KEY FACTORS AND PROSPECTS OF BIOECONOMY: RESOURCES, SUSTAINABLE DEVELOPMENT, TECHNOLOGIES AND MARKETS.......................................................................................................... FAIZOV T.H.............................................................................................................................................. GENE-DEPENDENT ANALYSIS AND FORECASTING OF ECONOMIC VALUE OF AGRICULTURAL ANIMALS................................................................................................................................................ FATYCHOV J.A., BESTUGHEV A.S., BALASHOV S.O., SUSLOV A.E....................................................... METHOD OF FISH DRY SALTING........................................................................................................... FATYCHOV J.A., SUSLOV A.E., MAHGAROV A.V................................................................................. TECHNOLOGY OF FUNCTIONAL FOOD ADDITION FROM FISH BONE............................................. FABIO FAVA1, D. DI GIOIA1,2, L. SCIUBBA 1, M. RUZZI3..................................................................... WHEAT BRAN AS A SOURCE OF FERULIC ACID FOR THE BIOLOGICAL PRODUCTION OF VANILLIN................................................................................................................................................................ FABIO FAVA1, LORENZO BERTIN1, SILVIA LAMPIS2, GIOVANNI VALLINI2, LEONARDO MARCHETTI1,................................................................................................................................................................. BIOFILM REACTORS PACKED WITH CERAMIC FILTERS OR GRANULAR ACTIVATED CARBON FOR THE ACIDOGENIC DIGESTION OF OLIVE MILL WASTEWATERS.............................................................................................................................................. FABIO FAVA1, GIULIO ZANAROLI1, ANDREA NEGRONI1, ANNALISA BALLOI2, DANIELE DAFFONCHIO2, LILY Y. YOUNG3.......................................................................................................... DETECTION OF A DEHALOCOCCOIDES-LIKE BACTERIUM AND A NEW REDUCTIVE DEHALOGENASE GENE IN PCB-DECHLORINATIONG CULTURES ENRICHED FROM A MARINE SEDIMENT OF VENICE LAGOON............................................................................ FAVA F.1, D. FRASCARI2, R. CIAVARELLI2, D. PINELLI2........................................................................ AEROBIC COMETABOLIC BIODEGRADATION OF CHLOROFORM IN A SAND-FILLED COLUMN REACTOR....................................... FABIO FAVA1, KEITH WALDRON2,CARLOS BALD3, ANDRS SEBK4, JAN BROEZE5, VICTOR M.



Pages:     | 1 |   ...   | 11 | 12 || 14 |
 
 >>  ()





 
<<     |    
2013 www.libed.ru - -

, .
, , , , 1-2 .